ダウンロード数: 238
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
52_481.pdf | 371.2 kB | Adobe PDF | 見る/開く |
完全メタデータレコード
DCフィールド | 値 | 言語 |
---|---|---|
dc.contributor.author | 白木, 良一 | ja |
dc.contributor.author | 桑原, 勝孝 | ja |
dc.contributor.author | 櫻井, 孝彦 | ja |
dc.contributor.author | 丸山, 高広 | ja |
dc.contributor.author | 星長, 清隆 | ja |
dc.contributor.alternative | Shiroki, Ryoichi | en |
dc.contributor.alternative | Kuwahara, Yoshitaka | en |
dc.contributor.alternative | Sakurai, Takahiko | en |
dc.contributor.alternative | Maruyama, Takahiro | en |
dc.contributor.alternative | Hoshinaga, Kiyotaka | en |
dc.date.accessioned | 2010-05-25T08:28:46Z | - |
dc.date.available | 2010-05-25T08:28:46Z | - |
dc.date.issued | 2006-06 | - |
dc.identifier.issn | 0018-1994 | - |
dc.identifier.uri | http://hdl.handle.net/2433/113868 | - |
dc.description.abstract | We performed an investigative and clinical study of docetaxel, and evaluated its efficacy against hormone-refractory prostate carcinoma (HRPC). In an in vitro experiment, docetaxel suppressed the human prostate cell line proliferation not only in an androgen-dependent cell line, LNCaP, but also in androgen-independent cell line, PC-3, in a dose-dependent manner. In an in vivo experiment applying an SCID mouse xenograft model with PC-3, docetaxel administration suppressed the tumor growth more than 95%. In a clinical study, eight cases were enrolled to low-dose (20 mg/m2/wk) weekly regimen and an other eight to high-dose (60 mg/m2/wk) administration of docetaxel every three weeks. A prostate specific antigen (PSA) decline of more than 50% were observed in 4 (50%) in the low-dose group and 5 (63%) in the high-dose group. The median time to progression and overall survival were 8.5 and 13.2 months in the low-dose group and more than 5.5 and 8.5 months in the high-dose one, respectively. This regimen was well tolerated, and the incidence of adverse effect was relatively low and light. Grade 3 neutropenia or leukocytopenia without fever was seen in three patients (18.8%). Only one patient required administration of granulocyte-colony stimulating factor because of neutropenia. No other grade 3 or 4 toxicity was observed. In conclusion, docetaxel-based chemotherapy was well tolerated and an active treatment for HRPC cases. | en |
dc.format.mimetype | application/pdf | - |
dc.language.iso | jpn | - |
dc.publisher | 泌尿器科紀要刊行会 | ja |
dc.subject | Hormone-refractory prostate carcinoma | en |
dc.subject | Chemotherapy | en |
dc.subject | Taxanes | en |
dc.subject.ndc | 494.9 | - |
dc.title | ホルモン不応性前立腺癌に対するタキサン系薬剤の有効性 | ja |
dc.title.alternative | Effectiveness of taxanes-based chemotherapy against hormone-refractory prostate carcinoma | en |
dc.type | departmental bulletin paper | - |
dc.type.niitype | Departmental Bulletin Paper | - |
dc.identifier.ncid | AN00208315 | - |
dc.identifier.jtitle | 泌尿器科紀要 | ja |
dc.identifier.volume | 52 | - |
dc.identifier.issue | 6 | - |
dc.identifier.spage | 481 | - |
dc.identifier.epage | 485 | - |
dc.textversion | publisher | - |
dc.sortkey | 14 | - |
dc.address | 藤田保健衛生大学泌尿器科 | ja |
dc.address.alternative | The Department of Urology, Fujita Health University School of Medicine | en |
dc.identifier.pmid | 16848362 | - |
dcterms.accessRights | open access | - |
dc.identifier.pissn | 0018-1994 | - |
dc.identifier.jtitle-alternative | Acta urologica Japonica | la |
dc.identifier.jtitle-alternative | Hinyokika Kiyo | en |
出現コレクション: | Vol.52 No.6 |
![](/dspace/image/articlelinker.gif)
このリポジトリに保管されているアイテムはすべて著作権により保護されています。